NCT07059299 2025-12-19
NeoTISLEGA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Recruiting
Clinical Trials
16 trialsNCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT06157996 2025-05-30
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06914687 2025-04-06
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06871527 2025-03-12
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06760858 2025-01-07
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
Southwest Hospital, China
Recruiting
NCT06451211 2024-06-11
Neo-ICEBOAT
Sun Yat-sen University
Phase 2 Recruiting
NCT04799548 2024-05-23
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06374901 2024-04-19
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06238167 2024-02-02
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06034964 2023-09-13
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT05687357 2023-04-19
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05536102 2023-03-09
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05325528 2023-02-01
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Zhejiang University
Phase 2/3 Unknown
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown